Literature DB >> 33584298

Extracellular ATP Mediates Cancer Cell Migration and Invasion Through Increased Expression of Cyclooxygenase 2.

Shilpa Sharma1, Harshit Kalra1, Ravi Shankar Akundi1.   

Abstract

The tumor microenvironment plays a major role in the ability of the tumor cells to undergo metastasis. A major player of tumors gaining metastatic property is the inflammatory protein, cyclooxygenase 2 (COX-2). Several tumors show upregulation of this protein, which has been implicated in mediating metastasis in various cancer types such as of colon, breast and lung. In this report, we show that the concentration of extracellular ATP (eATP) is increased in response to cell death mediated by chemotherapeutic agents such as doxorubicin. By using three different cell-lines-HeLa (cervical), IMR-32 (neuronal) and MCF-7 (breast)-we show that this eATP goes on to act on purinergic (P2) receptors. Among the various P2 receptors expressed in these cells we identified P2X7, in IMR-32 and MCF-7 cells, and P2Y12, in HeLa cells, as important in modulating cell migration and invasion. Downstream of the P2 receptor activation, both p42/44 mitogen-activated protein kinase (MAPK) and the p38 MAPK are activated in these cells. These result in an increase in the expression of COX-2 mRNA and protein. We also observe an increase in the activity of matrix metalloproteinase 2 (MMP-2) enzyme in these cells. Blocking the P2 receptors not only blocks migration and invasion, but also COX-2 synthesis and MMP-2 activity. Our results show the link between purinergic receptors and COX-2 expression. Increased levels of ATP in the tumor microenvironment, therefore, leads to increased COX-2 expression, which, in turn, affords migratory and invasive properties to the tumor. This provides P2 receptor-based anti-inflammatory drugs (PBAIDs) a potential opportunity to be explored as cancer therapeutics.
Copyright © 2021 Sharma, Kalra and Akundi.

Entities:  

Keywords:  COX-2; P2 receptor; PBAIDs; cancer recurrence; metastasis; prostaglandin E2; residual ATP; tumor microenvironment

Year:  2021        PMID: 33584298      PMCID: PMC7873692          DOI: 10.3389/fphar.2020.617211

Source DB:  PubMed          Journal:  Front Pharmacol        ISSN: 1663-9812            Impact factor:   5.810


  96 in total

Review 1.  Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2.

Authors:  R A Gupta; R N Dubois
Journal:  Nat Rev Cancer       Date:  2001-10       Impact factor: 60.716

2.  COX-2 involvement in breast cancer metastasis to bone.

Authors:  B Singh; J A Berry; A Shoher; G D Ayers; C Wei; A Lucci
Journal:  Oncogene       Date:  2007-01-08       Impact factor: 9.867

3.  Expression of P2X7 receptor increases in vivo tumor growth.

Authors:  Elena Adinolfi; Lizzia Raffaghello; Anna Lisa Giuliani; Luigi Cavazzini; Marina Capece; Paola Chiozzi; Giovanna Bianchi; Guido Kroemer; Vito Pistoia; Francesco Di Virgilio
Journal:  Cancer Res       Date:  2012-04-13       Impact factor: 12.701

Review 4.  P2X7 in Cancer: From Molecular Mechanisms to Therapeutics.

Authors:  Romain Lara; Elena Adinolfi; Catherine A Harwood; Mike Philpott; Julian A Barden; Francesco Di Virgilio; Shaun McNulty
Journal:  Front Pharmacol       Date:  2020-06-04       Impact factor: 5.810

5.  Interleukin-1beta induces cyclooxygenase-2 and prostaglandin E(2) synthesis in human neuroblastoma cells: involvement of p38 mitogen-activated protein kinase and nuclear factor-kappaB.

Authors:  B L Fiebich; B Mueksch; M Boehringer; M Hüll
Journal:  J Neurochem       Date:  2000-11       Impact factor: 5.372

Review 6.  Nucleotide signalling during inflammation.

Authors:  Marco Idzko; Davide Ferrari; Holger K Eltzschig
Journal:  Nature       Date:  2014-05-15       Impact factor: 49.962

7.  ATP, a double-edged sword in cancer.

Authors:  Jean X Jiang; Manuel A Riquelme; Jade Z Zhou
Journal:  Oncoscience       Date:  2015-08-30

8.  Doxorubicin Promotes Migration and Invasion of Breast Cancer Cells through the Upregulation of the RhoA/MLC Pathway.

Authors:  Chien-Liang Liu; Ming-Jen Chen; Jiunn-Chang Lin; Chi-Hsin Lin; Wen-Chien Huang; Shih-Ping Cheng; Shan-Na Chen; Yuan-Ching Chang
Journal:  J Breast Cancer       Date:  2019-04-22       Impact factor: 3.588

9.  P2X7 mediates ATP-driven invasiveness in prostate cancer cells.

Authors:  Ying Qiu; Wei-Hua Li; Hong-Quan Zhang; Yan Liu; Xin-Xia Tian; Wei-Gang Fang
Journal:  PLoS One       Date:  2014-12-08       Impact factor: 3.240

10.  Extracellular nucleotides as novel, underappreciated pro-metastatic factors that stimulate purinergic signaling in human lung cancer cells.

Authors:  Gabriela Schneider; Talita Glaser; Claudiana Lameu; Ahmed Abdelbaset-Ismail; Zachariah Payne Sellers; Marcin Moniuszko; Henning Ulrich; Mariusz Z Ratajczak
Journal:  Mol Cancer       Date:  2015-11-24       Impact factor: 27.401

View more
  5 in total

Review 1.  The circadian regulation of extracellular ATP.

Authors:  Xin Wang; Yu-Ting Dong; Xiu-Ming Hu; Ji-Zhou Zhang; Nan-Rui Shi; Yan-Qin Zuo; Xu Wang
Journal:  Purinergic Signal       Date:  2022-08-08       Impact factor: 3.950

2.  Cost-Effective Production of ATP and S-Adenosylmethionine Using Engineered Multidomain Scaffold Proteins.

Authors:  Guangbo Yan; Xia Li; Jun Yang; Zhongchen Li; Jia Hou; Ben Rao; Yong Hu; Lixin Ma; Yaping Wang
Journal:  Biomolecules       Date:  2021-11-17

Review 3.  P2Y12 Purinergic Receptor and Brain Tumors: Implications on Glioma Microenvironment.

Authors:  Fernanda Bueno Morrone; Pedro Vargas; Liliana Rockenbach; Thamiris Becker Scheffel
Journal:  Molecules       Date:  2021-10-12       Impact factor: 4.411

4.  P2X7 promotes metastatic spreading and triggers release of miRNA-containing exosomes and microvesicles from melanoma cells.

Authors:  Anna Pegoraro; Elena De Marchi; Manuela Ferracin; Elisa Orioli; Michele Zanoni; Cristian Bassi; Anna Tesei; Marina Capece; Emi Dika; Massimo Negrini; Francesco Di Virgilio; Elena Adinolfi
Journal:  Cell Death Dis       Date:  2021-11-16       Impact factor: 8.469

Review 5.  Melatonin: Regulation of Prion Protein Phase Separation in Cancer Multidrug Resistance.

Authors:  Doris Loh; Russel J Reiter
Journal:  Molecules       Date:  2022-01-21       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.